In vitro pharmacodynamic characteristics of griseofulvin against dermatophyte isolates of Trichophyton tonsurans from tinea capitis patients

Medical Mycology

Volumn 47, Issue 8, 2009, Pages 796-801

  Gupta, Aditya K ^a,b   Williams, Judith V ^c   Zaman, Muhammad ^a   Singh, Jagpal ^a  

^a MEDIPROBE RESEARCH INC   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Children s Specialty Group   (United States)

Author keywords

Antifungal; Dermatophyte; Griseofulvin; Resistance

Indexed keywords

GRISEOFULVIN; ANTIFUNGAL AGENT;

ADULT; ARTICLE; CHILD; COLONY FORMING UNIT; CONTROLLED STUDY; DERMATOPHYTE; DRUG SENSITIVITY; FUNGUS ISOLATION; GEOMETRY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; TINEA CAPITIS; TRICHOPHYTON TONSURANS; TRICHOPHYTON VIOLACEUM; ANTIFUNGAL RESISTANCE; AREA UNDER THE CURVE; ARTHRODERMATACEAE; DRUG EFFECTS; KINETICS; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; MICROSPORUM; TRICHOPHYTON;

MICROSPORUM CANIS; TRICHOPHYTON TONSURANS; TRICHOPHYTON VIOLACEUM;

ANTIFUNGAL AGENTS; AREA UNDER CURVE; ARTHRODERMATACEAE; DRUG RESISTANCE, FUNGAL; GRISEOFULVIN; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MICROSPORUM; TINEA CAPITIS; TRICHOPHYTON;

EID: 73649094426     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780802712523     Document Type: Article

References (28)

1. Chan YC, Friedlander SF. Therapeutic options in the treatment of tinea capitis. Expert Opin Pharmacother 2004; 5: 219-227.
2. Gupta AK, Summerbell RC. Tinea capitis. M ed Mycol 2000; 38: 255-287.
3. Roberts BJ, Friedlander SF. Tinea capitis: a treatment update. Pediatr Ann 2005; 34: 191-200.
4. Fuller LC, Smith CH, Cerio R, et al. A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis. Br J Dermatol 2001; 144: 321-327.
5. Gupta AK, Adam P, Dlova N, et al. Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. Pediatr Dermatol 2001; 18: 433-438.
6. Haroon TS, Hussain I, Aman S, et al. A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. Br J Dermatol 1996; 135: 86-88.
7. Lipozencic J, Skerlev M, Orofino-Costa R, et al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol 2002; 146: 816-823.
8. Lopez-Gomez S, Del Palacio A, Van Cutsem J, et al. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children. Int J Dermatol 1994; 33: 743-747.
9. Howard DH. Pathogenic Fungi in Humans and Animals.
10. Straughn AB, Meyer MC, Raghow G, Rotenberg K. Bioavailability of microsize and ultramicrosize griseofulvin products in man. J Pharmacokinet Biopharm 1980; 8: 347-362.
11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.
12. Singh J, Zaman M, Gupta AK. Evaluation of microdilution and disk diffusion methods for antifungal susceptibility testing of dermatophytes. Med Mycol 2007; 45: 595-602.
13. Fleece D, Gaughan JP, Aronoff SC. Griseofulvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials. Pediatrics 2004; 114: 1312-1315.
14. Silverberg NB, Weinberg JM, DeLeo VA. Tinea capitis: focus on African American women. J Am Acad Dermatol 2002; 46: S120-S124.
15. Williams JV, Eichenfield LF, Burke BL, Barnes-Eley M, Friedlander SF. Prevalence of scalp scaling in prepubertal children. Pediatrics 2005 ; 115 : e1-e6.
16. Mohrenschlager M, Korting HC, Seidl HP, Ring J, Abeck D. Tinea capitis. Therapeutic options in the post-griseofulvin era. Hautarzt 2002; 53: 788-794.
17. Jessup CJ, Warner J, Isham N, Hasan I, Ghannoum MA. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 2000; 38: 341-344.
18. Perea S, Fothergill AW, Sutton DA, Rinaldi MG. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J Clin Microbiol 2001; 39: 385-388.
19. Favre B, Hofbauer B, Hildering KS, Ryder NS. Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay. J Clin Microbiol 2003; 41: 817-4819.
20. Chadeganipour M, Nilipour S, Havaei A. I n vitro evaluation of griseofulvin against clinical isolates of dermatophytes from Isfahan. Mycoses 2004; 47: 503-507.
21. Ghannoum M, Isham N, Sheehan D. Voriconazole susceptibilities of dermatophyte isolates obtained from a worldwide tinea capitis clinical trial. J Clin Microbiol 2006; 44: 2579-2580
22. Osborne CS, Hofbauer B, Favre B, Ryder NS. I n vitro analysis of the ability of Trichophyton rubrum to become resistant to terbinafine. Antimicrob Agents Chemother 2003; 47: 3634-3636.
23. Manavathu EK, Vazquez JA, Chandrasekar PH. Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agent. Int J Antimicrob Agents 1999; 12: 213-219.
24. Cross EW, Park S, Perlin DS. Cross-Resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis. Microb Drug Resist 2000; 6: 155-161.
25. Epstein WL, Shah VP, Riegelman S. Griseofulvin levels in stratum corneum. Study after oral administration in man. Arch Dermatol 1972; 106: 344-348.
26. Shah VP, Riegelman S, Epstein WL. Determination of griseofulvin in skin, plasma, and sweat. J Pharm Sci 1972; 61: 634-636.
27. Shah VP, Epstein WL, Riegelman S. Role of sweat in accumulation of orally administered griseofulvin in skin. J Clin Invest 1974; 53: 1673-1678.
28. Sobue S, Sekiguchi K, Nabeshima T. Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum. Antimicrob Agents Chemother 2004; 48: 216-223.